M
Minoryx Therapeutics
Biotech & Life Sciences · Mataró, Spain · Founded 2011
Clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs MoreLess
Minoryx Therapeutics is a biotechnology startup dedicated to discovering and developing innovative treatments for severe, rare diseases of the central nervous system (CNS). These conditions, often referred to as orphan diseases, have high unmet medical needs, meaning there are few or no effective treatments available. The company is headquartered in Gosselies, Charleroi, Belgium.
Minoryx primarily targets patients suffering from life-threatening neurodegenerative disorders. Their leading program focuses on a compound called leriglitazone, a novel and selective PPAR gamma agonist. This compound is currently in clinical development for multiple orphan CNS disorders, with its primary indication being X-linked Adrenoleukodystrophy (X-ALD), a severe neurodegenerative disease.
The company operates in the biopharmaceutical market, which involves the research, development, and commercialization of drugs. Minoryx's business model revolves around the development and licensing of its proprietary treatments. They generate revenue through partnerships and licensing agreements with other pharmaceutical companies. For instance, Minoryx has an exclusive license agreement with Sperogenix Therapeutics to develop and commercialize leriglitazone in mainland China, Hong Kong, and Macau.
Minoryx has also received significant financial backing to support its research and development efforts. The European Investment Bank has provided substantial funding, and the company has received a fast-track designation from the US FDA for leriglitazone in the treatment of X-ALD. This designation helps expedite the development and review process for drugs that treat serious conditions and fill an unmet medical need.
In summary, Minoryx Therapeutics is at the forefront of developing breakthrough therapies for rare CNS diseases, aiming to bring new hope to patients with limited treatment options.
Keywords: Biotechnology, CNS diseases, Orphan diseases, Neurodegenerative, Leriglitazone, X-ALD, Drug development, Licensing, Clinical trials, FDA fast track.
Company overview
Minoryx Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- Mataró, Spain
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 69.2
- Investment activity
- 1 companies · latest Jul 2017
- Capital deployed
- $0
- Preferred round
- CORPORATE SPINOUT
Valuation & funding
Minoryx Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2025 | $30M | — | Undisclosed | ↗ |
| SERIES COther financing | May 2022 | $26M | $102M | Ysios Capital · FundPlus · Criteria Venture Tech · CDTI Innvierte | ↗ |
| DEBTDebt | May 2022 | $26M | — | Criteria Venture Tech · Columbus Venture Partners · FundPlus · Ysios Capital | ↗ |
| GRANTOther financing | Oct 2020 | $28M | — | European Investment Bank | — |
| SERIES BOther financing | Sep 2018 | $23M | $94M | Criteria Venture Tech · Eurazeo · Chiesi Ventures · Roche Venture Fund | ↗ |
| GRANTOther financing | May 2018 | European Innovation Council | — | ||
| SERIES AOther financing | Oct 2015 | HealthEquity · Roche Venture Fund · Criteria Venture Tech · Eurazeo | — | ||
| EARLY VCOther financing | Jan 2015 | Criteria Venture Tech | — | ||
| SERIES AOther financing | Apr 2013 | Criteria Venture Tech · Inveready | — | ||
| GRANTOther financing | Dec 2012 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $5.7M | 0% | −$1.1M | -18.4% |
| 2025 | $5.7M | 0% | −$1.1M | -18.4% |
| 2024 | $5.7M | 0% | −$1.1M | -18.4% |
| 2023 | $5.7M | -83.3% | −$1.1M | -18.4% |
| 2022 | $34M | +7665.7% | −$1.1M | -3.1% |
| 2021 | $443K | -90.1% | −$1.1M | -238.1% |
| 2020 | $4.5M | — | −$1.1M | -25.4% |
Growth signals
Minoryx Therapeutics website traffic
Latest recorded traffic for Minoryx Therapeutics is 5.3K monthly website visits, up 10.4% over the last three months. Minoryx Therapeutics's team grew 3.1% over the past year.
Comparisons
Minoryx Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Minoryx Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Minoryx Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on Minoryx Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Minoryx Therapeutics has talent and traffic
team presence
In the news
Latest news about Minoryx Therapeutics
Recent press, funding announcements, and product moves mentioning Minoryx Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Minoryx Therapeutics
An AI-synthesized read of the highest-engagement posts about Minoryx Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Minoryx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.